Summary of CAN AGM 29/11/19, page-28

like mining coys its all done in stages. Initially theyll produce upto 20 to be prudent and cater to australia matket n nz markets. They have finished product medicine w label to sell thru Drs n pharmacies now.

Aurrora Is Supporting us . Any excess in nxt 2-3yrs we can supply them ready made medicine. We wont be up n running anyways till mid 2021 in a proper way similar to minimg companies being in commissioning stages of early production. We have money till its all built aaid pe

ter crock -.ie thy are cutting dwn on the 20mill capex for nxt qtr . Well have 15mill for all of next yr if they do this cost cut in capex. Easy. In meantime with finished product ready for sale , well have a backorder of medicine to supply drs n pharmacies. The nth n sth facilities can cater for this , so well have cashflow coming in from finished mm product sales for 2020 too and 2021 into commissioning n production in 2021. By 2022 the market in oz will have grown by 50pct yr on yr from 2019. In 2023 again... Nz is a massive mkt 1.5hrs away from Aus . With finished product sales can increase by selling to them (we invested 6mill into nz footprint!).

Theres plenty of growing demand n patients trying to seek mm yr on yr. Relax. We near or at bottom. We have a labelled medicine now to sell here n in nz! Cashflow. Well get a 30-40kill loan bank is with us. We have aurrora support . Well start by selling our product now. By production well have a backlog of orders from aus-nz already....